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Purpose: Adenoviral keratoconjunctivitis is recognized as one of the major pathogens of oph-
thalmological nosocomial infection worldwide. N-Chlorotaurine (Cl–HN–CH2–CH2–SO3H, 
NCT) is the N-chloro derivative of the amino acid taurine, which is an oxidant produced by 
human granulocytes and monocytes during inflammatory reactions. Using conventional viral 
plaque assay, it was previously shown that NCT causes inactivation of several human adenovirus 
(HAdV) serotypes. In this study, we evaluated the antiadenoviral effect of NCT by quantitative 
polymerase chain reaction (PCR) methods.
Methods: A549 cells were used for viral cell culture, and HAdV serotypes 3, 4, 8, 19, and 
37 were used. After calculating 50% cytotoxic concentration (CC50) of NCT by MTS (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) method, 
HAdV was cultured with NCT for 7 days, and extracted adenoviral DNA was quantitatively 
measured by real-time PCR.
Results: A statistically significant (P , 0.05) dose-dependent inhibition was indicated for all 
serotypes except HAdV type 4 (HAdV4), which was maximally inhibited by only ∼50%. Among 
the serotypes, NCT was particularly effective against HAdV8, HAdV19a, and HAdV37. The 50% 
effective concentration (EC50) obtained by real-time PCR of NCT ranged between 49 and 256 µM. 
EC50 of NCT against HAdV3 was slightly higher than that against serotypes of species D. 
The selective index (CC50/EC50) ranged between 41 and 60 except for HAdV4 (11.5).
Conclusions: These results show that NCT has an antiviral effect against most serotypes of 
human HAdV inducing keratoconjunctivitis, indicating its possible therapeutic use.
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Introduction
The human adenovirus (HAdV) family consists of 55 known types, which are divided 
into seven species, A–G.1,2 The most common external ocular viral infections world-
wide are caused by many HAdV serotypes.3,4 Infectious diseases caused by HAdV 
include respiratory tract infection, keratoconjunctivitis, hemorrhagic cystitis, and 
arthritis, some of which may result in a lethal outcome in immunocompromised persons. 
  The growing practice of transplantation accompanied by strong   immunosuppressive 
therapy in recent decades has led to a gradual increase in the incidence of severe HAdV 
infections. Pediatric patients undergoing allogeneic stem cell   transplantation are par-
ticularly prone to disseminated HAdV infections, with high associated   morbidity and 
mortality.5 Severe systemic HAdV infection can also occur in patients with acquired 
immune deficiency syndrome.6 In particular, adenoviral conjunctivitis is known to 
be the major cause of acute contagious infections associated with community and 
nosocomial epidemics.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Thus, the development of effective anti-AdV drugs 
for the clinical treatment of adenoviral conjunctivitis and 
  systemic HAdV infectious diseases is important. However, 
there is no approved antiviral therapy for HAdV infections 
at this time. In potentially lethal HAdV infections, medical 
treatment is currently carried out using antiviral agents, 
especially nucleotide analogs. Among nucleotide analogs, 
ribavirin,7 trifluridine,8 and cidofovir9–12 are reported to be 
effective in vitro against HAdV. We have recently reported 
that nucleoside reverse transcriptase inhibitors,   zalcitabine 
and stavudine, both show significant antiadenoviral 
activity.13
N-Chlorotaurine (Cl–HN–CH2–CH2–SO3H, NCT) is 
the N-chloro derivative of the amino acid taurine. NCT is 
the main representative of long-lived oxidants produced by 
stimulated granulocytes and monocytes during inflamma-
tory reactions.14–16 It has been demonstrated that NCT has 
significant in vitro microbicidal activity against bacteria, 
yeasts, and molds.17,18 NCT has also been shown to be 
  virucidal in vitro against HAdV serotype 5.19 The cytotox-
icity of NCT to human cells in vitro is very low compared 
with that of powerful oxidants such as hypochlorite.20 Using 
a plaque assay, Romanowski et al previously reported that 
NCT demonstrated inhibitory effect against HAdV serotypes 
1, 2, 3, 4, 5, 7a, 8, 19, and 37.21 In a clinical trial of 1% NCT 
application in epidemic keratoconjunctivitis, safety and 
clinical usefulness were observed; however, the number of 
participants was limited and virological analysis was not 
carried out in that study.22
In the present study, using real-time polymerase chain 
reaction (PCR) method to directly quantify HAdV progeny 
in virus-infected cells, we investigated whether NCT displays 
potent and selective antiviral activity against HAdV serotypes 
causing keratoconjunctivitis, serotypes 3, 4, 8, 19a, and 37.
Materials and methods
experimental compound
NCT, which was donated by Dr Nagl (Innsbruck, Austria), was 
prepared as the crystalline sodium salt (MW = 181.57 g/mol). 
It was dissolved in phosphate-buffered saline at various con-
centrations for in vitro antiviral assay as described later.
Cells
A549 cells (alveolar epithelial cells; ATCC #CCL-185) were 
obtained from the American Type Culture Collection (ATCC, 
Manassas, VA) and cultured in Eagle’s minimum essential 
medium containing 2 mM l-glutamine, 0.1 mM nonessential 
amino acids, and 7% fetal calf serum.
Viruses
The viruses used were HAdV type 3 (HAdV3), HAdV4, 
HAdV8, HAdV19, and HAdV37. Four types, HAdV3, 
HAdV4, HAdV8, and HAdV37, were prototype strains and 
were provided by the ATCC. HAdV19a was a clinical strain23 
because HAdV19a is frequently associated with epidemic 
keratoconjunctivitis, whereas the prototype of HAdV19 
(HAdV19p) is not responsible for outbreaks of keratocon-
junctivitis.24 These strains were propagated in A549 cells and 
stored at −80°C until use.
Cytotoxicity assay
The cytotoxicity of NCT was evaluated in uninfected con-
fluent A549 cells in 96-well plates (Falcon 3072; Becton 
Dickinson, Lincoln Park, NJ). Dilutions of NCT were pre-
pared in Eagle’s minimum essential medium supplemented 
with 2% fetal calf serum. Seven concentrations (15, 30, 60, 
120, 240, 480, and 960 µg/mL) of the test compound were 
used. After 7 days of incubation at 37°C with 5% CO2, the 
cells were subjected to a 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium 
(MTS)-based colorimetric viability assay according to 
the manufacturer’s instructions (Promega, Leiden, The 
  Netherlands). A490 values, corrected for the cytotoxicity 
exerted by NCT (as determined in mock-infected cultures), 
were used to calculate the percent cell viability. The 50% 
cytotoxic concentration (CC50) of NCT corresponds to a 50% 
reduction in cell viability.
Antiviral analysis in A549 cells  
by real-time PCr
First, A549 cells were seeded in wells of 96-well plates 
at 10,000 cells/well and incubated for 4 or 5 days until 
confluency was reached. Then HAdV in 50 µL was added 
to 5 PFU/well. After 2 h at 37°C, the virus suspension 
was aspirated and replaced by serial dilutions of NCT 
(200 µL/well). The concentrations of NCT ranged between 
1/80 and 1/10 of the CC50 of NCT. Mock-infected cultures 
receiving only NCT were included in each plate. After 
7 days of incubation at 37°C, microscopy was performed 
to score the virus-induced cytopathic effect (CPE). After 
removal of the culture supernatant, cells and virus particles 
were lysed by the addition of 70 µL lysis buffer (10 mM 
Tris-HCl (pH 7.8), 0.5% sodium dodecyl sulfate, 5 mM 
Na2EDTA, and 80 µg proteinase K/mL) and incubated 
at 50°C for 1 h and then at 65°C for 20 min to inactivate 
  proteinase K. After centrifugation (23,000 × g, 10 min), 
soluble cell extracts were stored at −20°C until real-time Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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PCR was performed. Extracts were diluted 100-fold in 
water. Then 2 µL of diluted extract was added to each well 
in optical plates containing 23 µL SYBR green PCR master 
mix (Applied Biosystems, Foster City, CA), and forward 
and reverse primers (300 µM) were added to the wells. The 
primers, derived from GenBank sequences, were chosen to 
amplify a 137-bp fragment in the conserved HAdV hexon 
DNA sequence, allowing analysis of all known HAdV types 
(forward primer, 5′-CGCTGGACATGACTTTTGAG-3′; 
reverse primer, 5′-GAACGGTGTGCGCAGGTA-3′). 
Real-time PCR analysis was performed in an ABI Prism 
7000 apparatus (Applied Biosystems) and consisted of 
10-min activation at 95°C, followed by 40 thermal cycles, 
each consisting of 15 s at 95°C and 90 s at 60°C. The dis-
sociation profile was obtained at the end of each analysis 
to confirm the specificity of the PCR amplification. In each 
individual experiment, a standard curve (R2 . 0.98 within 
the range of 103–108 copies/reaction mixture) was obtained 
by amplification of known amounts of a pGEM T-vector 
in which a 691-bp fragment of HAdV hexon DNA was 
inserted using common cloning procedures. These standard 
curves were used to convert the cycle threshold values for 
the A549 extracts into the absolute number of HAdV hexon 
DNA copies. The 50% effective concentration (EC50) was 
calculated from the dose response to NCT measured 7 days 
postinfection and corresponded to the NCT concentra-
tion reducing the number of viral DNA copies by 50%. 
All experiments were carried out in triplicate. The lower 
limit for the detection of HAdV in this study was 10 copies/
reaction as reported elsewhere.25
statistics
Nonparametric analysis was conducted. Shirley–Williams 
test was used to detect the significance of the dose- 
dependency of tested agent in each serotype. A level of 
P , 0.05 was accepted as statistically significant.
ethical consideration
This research adhered to the tenets of the Declaration of 
Helsinki.
Results
Cytotoxicity and antiviral activity  
of nCT and eC50
In the cytotoxicity assay for NCT, CC50 of NCT was 
530 µg/mL (2.9 mM). The relationship of the concentration 
of NCT and decrease in virus copy is shown in Table 1. EC50 
obtained by real-time PCR of NCT ranged between 48.9 
and 257 µM. Among the serotypes, NCT appeared to be 
particularly effective against HAdV37, and other serotypes 
belonging to species D, HAdV8 and HAdV19a, were simi-
larly sensitive to NCT. EC50 of NCT against HAdV3 was 
similar to that against species D serotypes. In contrast, EC50 
of NCT to HAdV4, species E, was greater than that for other 
serotypes, showing ∼fourfold lower antiadenoviral activity 
compared to that against species D serotypes. A statistically 
significant dose-dependent inhibitory effect (P , 0.05) was 
observed in all serotypes except for HAdV4.
selectivity index of nCT
Selective index (CC50/EC50) of NCT for each HAdV serotype 
was calculated based on the values of CC50 and EC50 of NCT. 
The results are shown in Table 2. Selective index of NCT for 
each HAdV serotype ranged between 11.5 and 60.2.
Discussion
NCT is a weak endogenous oxidative amine whose main 
mode of action appears to be oxidation of thio and amino 
groups of proteins, which provides broad-spectrum activity 
against pathogens26,27 with low probability of occurrence of 
resistance.22 No additives are considered to be necessary 
for storage and application of NCT, and allergic reactions 
Table 1 Antiviral activity of N-chlorotaurine against hAdV in A549 cells and eC50
N-Chlorotaurine  
conc (μg/mL)
No of HAdV copies/cell (log copies/mL)
HAdV type 3 
(HAdV3)
HAdV4 HAdV8 HAdV19a HAdV37
53   9.40 ± 0.17*   9.73 ± 0.06 7.41 ± 0.94*   9.89 ± 0.47*   9.34 ± 0.66*
27   9.86 ± 0.05*   9.90 ± 0.01 7.63 ± 0.76* 10.01 ± 0.06*   9.73 ± 0.55*
13.5 10.07 ± 0.05*   9.96 ± 0.03 8.18 ± 0.76 10.24 ± 0.07*   9.93 ± 0.09*
6.8 10.23 ± 0.02* 10.01 ± 0.07 8.57 ± 0.02 10.67 ± 0.15 10.33 ± 0.31
0 10.40 ± 0.07 10.05 ± 0.21 8.64 ± 0.15 10.80 ± 0.04 10.54 ± 0.09
eC50 (µg/mL) 12.9 (71.7 µM) 46.2 (257 µM) 11.1 (61.7 µM) 9.5 (52.8 µM) 8.8 (48.9 µM)
Notes: A statistically significant dose-dependent inhibitory effect compared with control was observed in all serotypes except for AdV4. *P , 0.05.
Abbreviations: hAdV, human adenovirus; eC50, 50% effective concentration.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1328
Uchio et al
seem to be rare.21 NCT has the additional advantage of 
low   cytotoxicity against human cells in vitro compared 
with   powerful oxidants like hypochlorite.20 In the pres-
ent study, EC50s of NCT ranged between 49 and 256 µM, 
which would be 1/10–1/60 of its CC50 (2.9 mM), indicating 
  pharmacological safety as an antiviral agent.
From a survey of published studies, several kinds of 
in vitro methodology have been used for anti-HAdV testing, 
and three antiviral assays, 1) based on a classical CPE assay, 
2) MTS-based cell viability staining, and 3) direct quantita-
tion of virus progeny by real-time PCR, yielded similar and 
reproducible values of antiviral EC50.28 The finding of sig-
nificant inhibitory activity of NCT in the present study was 
similar to that reported by Romanowski et al.21 However, viral 
plaque assay based on conventional CPE assay was used in 
the report by Romanowski et al, and EC50 values were not 
determined in that report,21 whereas real-time PCR assay can 
provide less labor-intensive, more rapid, and equally reliable 
way of testing antivirals against HAdV .
In our present study, the antiviral activity of NCT against 
HAdV4, species E, was weaker than that against other 
serotypes and significant dose-dependency was not found. 
In contrast, EC50 of NCT against HAdV3, species B, and 
HAdV8, HAdV19a, and HAdV37, species D, showed 
similar values, and these serotypes showed a significant 
dose-dependent tendency. The reason for this is unclear, 
considering the nonspecific mode of action (oxidation of 
SH and NH groups) of NCT.22 As for receptors, HAdV4 
uses constitutive androstane receptor (CAR), in contrast to 
  serotypes belonging to species  B and D.29 A possible expla-
nation for the ineffectiveness of NCT peptide in HAdV4 may 
derive from the fact that HAdV4 manifests superior binding 
and infectivity in epithelial A549 cells compared to members 
of species B and D.30 In contrast, adenoviruses from species 
B and D show higher infectivity against human hematopoi-
etic cells than does HAdV4.31 These biological properties of 
HAdV4 in various cells suggest that HAdV4 has superior 
CAR capacity or uses an unknown co-receptor in addi-
tion to CAR,   leading to its lower susceptibility to NCT. 
Although statistically significant dose-dependent inhibitory 
effect of NCT against HAdV4 was not observed in this 
study,   dose-dependent inhibitory tendency was observed in 
HAdV4; thus this result might be due to restricted number 
of test samples, triplicate. In   addition, there is a possibility 
that NCT might be effective against HAdV4 similar to other 
serotypes studied here.
In conclusion, NCT was shown to be a potent and 
  selective agent against HAdV , and there is a possibility that 
NCT could be applied to the eye as eye drops or an ointment 
for adenoviral conjunctivitis. Further examination in both 
experimental and clinical contexts is necessary before its 
clinical use.
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